Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy... 
Via Benzinga
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
From Seagen Inc.
Via Business Wire
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,800 Today
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,000 Today
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
3 Stocks Worth Buying at 52-Week Lows
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors 
Via MarketBeat
Seagen Stockholders Approve Acquisition by Pfizer
From Seagen Inc.
Via Business Wire
Check Out What Whales Are Doing With SGEN
Via Benzinga
(SGEN) - Analyzing Seagen's Short Interest
Via Benzinga
$100 Invested In Seagen 5 Years Ago Would Be Worth This Much Today
Via Benzinga
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
Should Pfizer and Seagen investors be worried? 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News
The pharmaceutical giant wouldn't be borrowing if it didn't have plans for how to make a tidy return. 
Via The Motley Fool
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
Seagen's Return on Invested Capital Insights
Via Benzinga
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S. 
Via Benzinga
GDC Stock Alert: Why Is GD Culture Group Up 106% Today?
GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023. 
Via InvestorPlace
Why Is Guardforce AI (GFAI) Stock Up Today?
Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering. 
Via InvestorPlace
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?
Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares. 
Via InvestorPlace
Seagen (SGEN) Stock Falls 6% After Director Sells Shares
Seagen (SGEN) stock is slipping on Tuesday after one of the company's directors sold shares worth more than $372,000 on Monday. 
Via InvestorPlace
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way. 
Via Investor's Business Daily
Vaccine Sales Are Falling. Should You Still Buy Pfizer?
This is a transition year for Pfizer. 
Via The Motley Fool
7 High-Yield Dividend Stocks to Buy and Hold Forever
A stagnant market can be frustrating, but also a good time to look for high-yield dividend stocks to buy now. 
Via InvestorPlace
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Seagen Reports First Quarter 2023 Financial Results
From Seagen Inc.
Via Business Wire
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.